Impact of Discards for Living Donor Kidney Transplantation in a Transplant Program
Hilda Mercedes Villafuerte Ledesma(Hospital Clínico Universitario Lozano Blesa), Joan Cid(Hospital Clínic de Barcelona), Jaume Martorell(Hospital Clínic de Barcelona), Fritz Diekmann(Hospital Clínic de Barcelona), Josep M. Campistol(Universitat de Barcelona), David Cucchiari(European Association of Urology), Federico Oppenheimer(Hospital Clínic de Barcelona), David Paredes(Services Hospital), Mireía Musquera(Surgical Specialties (Canada)), Pedro Ventura‐Aguiar(Hospital Clínic de Barcelona), Lluís Peri(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Erika De Sousa‐Amorim(Hospital Clínic de Barcelona), Antonio Alcaraz(Hospital Clínic de Barcelona), Miquel Lozano(Unidad de Investigación en cuidados y servicios de salud (Investén-isciii)), Eduard Palou(Hospital Clínic de Barcelona)
Cited by 3
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566
In Vivo Activation of a Conserved MicroRNA Program Induces Mammalian Heart Regeneration
|Cell stem cell|2014|201
COVID-19 in transplant recipients: The Spanish experience
|American Journal of Transplantation|2020|200